Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

Sakura Sakajiri1, Takashi Kumagai, Norihiko Kawamata

  • 1Division of Hematology/Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA.

Experimental Hematology
|January 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Shyamsunder et al. THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. <i>Int. J. Mol. Sci.</i> 2022, <i>23</i>, 1207.

International journal of molecular sciences·2026
Same author

Harnessing MDM2-Mediated Targeted Degradation of Transcriptional and Epigenetic Machinery to Disrupt Oncogenic Addictions in Pediatric Sarcoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

qChIP-MS reveals the local chromatin composition by label-free quantitative proteomics.

Nature communications·2026
Same author

Editor's Note: Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

XPO1 inhibitor KPT-330 disrupts the core transcriptional regulatory circuitry of dedifferentiated liposarcoma by modulating the translation process.

Oncogene·2026
Same author

Author Correction: BCL6 enables Ph<sup>+</sup> acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Nature·2026

Histone deacetylase inhibitors (HDACIs) show promise for treating human lymphoid cancers by restoring tumor suppressor gene expression and inhibiting cancer cell proliferation. Both suberoylanilide hydroxamic acid (SAHA) and valproic acid demonstrated significant antiproliferative effects in vitro and in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Tumor suppressor gene silencing via DNA methylation and histone deacetylase (HDAC) recruitment is common in human cancers.
  • HDAC inhibitors (HDACIs) can reverse this silencing, restoring gene expression and inhibiting cancer cell growth.

Purpose of the Study:

  • To investigate the in vitro antiproliferative effects of HDACIs suberoylanilide hydroxamic acid (SAHA) and valproic acid on human lymphoid cancer cell lines.
  • To evaluate the efficacy and safety of SAHA in a preclinical mouse model of mantle cell lymphoma.

Main Methods:

  • Treatment of 14 human lymphoid cancer cell lines with SAHA and valproic acid.
  • Cell cycle analysis (G1 and G2-M arrest), apoptosis assays, and Western blotting for cell cycle regulatory proteins (cyclin D1, D2, p53, p21, p27).

Related Experiment Videos

  • Chromatin immunoprecipitation (ChIP) assay to assess histone acetylation at the p21 promoter.
  • In vivo efficacy study of SAHA in nude mice bearing mantle cell lymphoma xenografts.

    • Main Results:

    • All 14 lymphoid cancer cell lines were sensitive to the antiproliferative effects of HDACIs.
    • SAHA induced G1 or G2-M cell cycle arrest and apoptosis, downregulating cyclin D1/D2 and upregulating p53/p21/p27.
    • SAHA treatment increased histone acetylation at the p21 promoter, indicating restored gene accessibility.
    • SAHA significantly inhibited tumor growth in a mantle cell lymphoma mouse model with no major toxic side effects.

    Conclusions:

    • HDAC inhibitors, particularly SAHA, exhibit potent in vitro and in vivo antiproliferative activity against human lymphoid cancers.
    • SAHA demonstrates a favorable therapeutic profile, including cell cycle regulation, apoptosis induction, and tumor growth inhibition.
    • HDACIs represent a promising therapeutic strategy for human lymphoid malignancies.